---
title: "\"Performance\" BeOne Medicines achieved a GAAP net profit of USD 287 million for the year, turning a loss into a profit"
description: "BeOne Medicines announced its 2025 annual results, with a GAAP net profit of USD 287 million, turning around from a net loss of USD 645 million in the previous year. Total revenue reached USD 5.343 bi"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277055711.md"
published_at: "2026-02-26T14:06:16.000Z"
---

# "Performance" BeOne Medicines achieved a GAAP net profit of USD 287 million for the year, turning a loss into a profit

> BeOne Medicines announced its 2025 annual results, with a GAAP net profit of USD 287 million, turning around from a net loss of USD 645 million in the previous year. Total revenue reached USD 5.343 billion, a year-on-year increase of 40%. Earnings per share were 20 cents, with product revenue of USD 5.282 billion and global sales of USD 3.9 billion, growing by 49%. Free cash flow was USD 942 million. The guidance for fiscal year 2026 expects total revenue to be between USD 6.2 billion and USD 6.4 billion, with a GAAP gross margin expected to be at the high end of the 80% range

Beijing Beion Pharmaceuticals (06160.HK)(ONC.US) announced its fiscal year 2025 results, reporting total revenue of USD 5.343 billion, a year-on-year increase of 40%. It recorded a GAAP net profit of USD 287 million, compared to a net loss of USD 645 million in the previous year, turning a profit mainly due to revenue growth and improved operating leverage. Earnings per share were 20 cents.

Product revenue for 2025 was USD 5.282 billion, an increase of 40%, accounting for 99% of total revenue; among them, the global sales of Baiyueze reached USD 3.9 billion, a growth of 49%. The gross margin for global product sales increased from 85.5% in the previous year to 87.8%. Free cash flow was USD 942 million, an increase of USD 1.6 billion compared to the previous year.

For fiscal year 2026 guidance, total revenue is expected to be between USD 6.2 billion and USD 6.4 billion; GAAP gross margin is expected to be at the high end of the 80% range; GAAP operating profit is projected to be between USD 700 million and USD 800 million; non-GAAP operating profit is expected to be between USD 1.4 billion and USD 1.5 billion

### Related Stocks

- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [06160.HK - BEONE MEDICINES](https://longbridge.com/en/quote/06160.HK.md)
- [159929.CN - China Universal 800 Health Care ETF](https://longbridge.com/en/quote/159929.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [159102.CN - Huaan Hang Seng Biotech ETF](https://longbridge.com/en/quote/159102.CN.md)
- [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals | Hong Kong-listed Chinese pharmaceutical companies are poised for profitability due to rising drug sales and lucrative li | [Link](https://longbridge.com/en/news/277340041.md) |
| BeOne Medicines posts 2025 results and issues cautious 2026 outlook | BeOne Medicines Ltd, a biopharmaceutical company based in Switzerland and listed in Hong Kong, has released its unaudite | [Link](https://longbridge.com/en/news/277035413.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/en/news/276822785.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease | SinoMab Bioscience Ltd. has received approval from China's National Medical Products Administration for an investigation | [Link](https://longbridge.com/en/news/276765156.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.